About Zilia
Zilia is a medical device company that provides actionable information based on the measurement of biomarkers in the eye to facilitate earlier diagnosis, reduce healthcare costs, and improve the quality of life of patients.We are on a journey to save the sight and improve the health of millions.
We are Scientists, Researchers and Visionaries
Our team has years of experience in biotechnology and is based in Quebec City,
a world-renowned hub of expertise in optics and photonics.
Meet our Team
Sébastien Bouchard, CPA
CFO
Dario Zujo, MBA
Business Development Director
Joannie Desroches, PhD
Clinical Applications Specialist
Diana Martínez, PhD
Quality & Regulatory Affairs Specialist
Cléophace Akitegetse, PhD, PEng
Biophotonics and Data Analytics Lead Scientist
Nicolas Lapointe, MEng
Lead Engineer
Maxime Picard, Eng
Lead Software Engineer
Alex Gagné
Software Developer
Éric Hamel, MEng
AI Research Scientist
Isabelle Harvey, Eng, MSc
Product Manager
Jasmine Poirier, MSc
Computer Vision Specialist
Thierry Proulx, BASc
Software Developer
Marianne Régis
Software Developer
Board of Directors
Advisory Board
Dr. John G Flanagan, PhD, FCOptom, FAAO, FARVO
Dean & Professor at University of California, Berkeley
Would you like to join us?
We are always looking for positive, ambitious professionals who share our values and stand behind Zilia’s mission. Careerscontact usSolutions
As a trained optometrist, Patrick puts his in-depth understanding of the clinical care to the development of innovative technologies to revolutionize eye care and prevent vision loss. He is continuously contributing to clinical and innovative technological advancements to the field. Patrick is also a guest speaker at the school of optometry Université de Montréal, the university where he received his Doctor of Optometry (OD) degree and Master’s degree in Vision Science. He is an active member of the Association des Optométristes du Québec.
Dominic has an extensive experience working for the development of new technologies in industrial and academic environments for applications in biotechnology and bioengineering. He is associate Professor in the Department of Chemical and Materials Engineering at the University of Alberta, Dominic has a strong background and expertise in academic and industrial bioengineering.
Claude is an experienced leader and entrepreneur with 30+ years of experience in life sciences including clinical research, product development, sales, marketing, operations and business development. Claude also worked in the venture capital sector, playing a major role in the financing of numerous ventures.
Dominique is a certified Ophthalmologist and founder of a renowned private medical center. As an active clinical researcher in the field of ophthalmology, she provides valuable knowledge and insight into the development and application of Zilia’s technology.
Danny is a pharmacist-owner since 2002 and President of Gilbert Gobeil Martel Pharmacies, which is comprised of four pharmacies and 125 employees. Over the years, Danny has built a strong expertise in marketing, sales and business operations. He is also an active private investor in the healthcare sector.
Dr. Ahmed is a leader in novel treatments for glaucoma, cataract, and lens implant surgery. His pioneering work in glaucoma surgery includes developing micro-invasive glaucoma surgery (MIGS). An assistant professor at the University of Toronto and a professor at the University of Utah, he is also a research director at the Kensington Eye Institute and director of the Glaucoma and Advanced Anterior Segment Surgery (GAASS) fellowship, both at the University of Toronto. In addition, Dr. Ahmed is head of the ophthalmology division at Trillium Health Partners. He is recognized as one of the most experienced complex eye surgeons in the world.
Dr. Rajat N Agrawal is President and CEO of Retina Global, a not-for-profit organization addressing retinal diseases in underserved areas of the world, an Adjunct Professor at the Roski Eye Institute, and a Visiting Professor at the Dept. of Ophthalmology at the University of Southern California. He is a world-renowned ophthalmologist and retina specialist. He has been involved in developing a number of medical devices, including the ARGUS-II which allows some blind patients to see again, and drugs for the treatment of ocular diseases. He holds a Masters in Regulatory Affairs and works as a consultant for pre-clinical and clinical research, and business and market evaluation. He has been an advisor for investments and acquisitions of early to late-stage biomed opportunities, totaling over 50 million dollars.
John G Flanagan, PhD, DSchc, FCOptom, FAAO, FARVO
Dean & Professor at University of California, Berkeley
John G. Flanagan is the Dean and Professor at School of Optometry and Vision Science Program, University of California, Berkeley. Dr. Flanagan graduated in Optometry and Vision Sciences from Aston University, Birmingham, UK in 1980, where he later earned his PhD in 1985. During his career, he has received a multitude of honors for his work including the Certificate of Merit for Research Excellence (Glaucoma Research Society of Canada), the Glenn A Fry Award (American Academy of Optometry), and more recently, the President’s Award for services to the profession of optometry (American Optometric Association). He has supervised 45 graduate students and has authored over 175 peer-reviewed publications. In addition, he has 14 book chapters, 3 books and has given numerous invited lectures primarily focusing on ocular imaging to ocular blood flow and vascular reactivity.